Stockreport

ProKidney Announces Strategic Updates to its Phase 3 Program to Accelerate Rilparencel’s Registrational Path to Potential Approval in the U.S.

ProKidney Corp. - Class A Ordinary Shares  (PROK) 
PDF Refined the focus of the Phase 3 program to accelerate path to potential U.S. approval and commercial launch in the Company’s highest priority marketDiscontinued the ex- [Read more]